DL-α-Difluoromethylornithine (hydrochloride hydrate)
(Synonyms: 依氟鸟氨酸盐酸盐一水合物,DFMO,Eflornithine) 目录号 : GC12595
An irreversible inhibitor of ornithine decarboxylase
Cas No.:96020-91-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Animal experiment: |
Mice: The skin area where the hair is removed is then treated with the eflornithine hydrochloride 13.9% cream (-50 mg per mouse per treatment) using a spatula 2 times a day in an interval of at least 8 h for a maximum period of 36 days[3]. |
|
References: [1]. Burri C, et al. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003 Jun;90 Supp 1:S49-52. |
|
DL-α-Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase.
Ornithine decarboxylase catalyzes the decarboxylation of ornithine to form putrescine, which is the committed step in polyamine synthesis.
DFMO inhibited the polyamine synthesis process and displayed antiangiogenic and cytostatic effects in many human tumor cells. In rat bladder carcinoma cell line-804G cells, DFMO inhibited the growth of 804G cells stimulated by Fraction I or by 10% FCS [2].
In female SENCAR mice with skin tumorigenesis model, both oral intake of DFMO (1.5-2.0% wt/vol) and intraperitoneal injection of DFMO (20mg,i.p. and 5mg,i.p.) reduced the sizes and numbers of skin tumor compared to control group [3].
References:
1. H. M. Wallace, A. V. Fraser and A. Hughes. A perspective of polyamine metabolism. Biochemistry Journal 376(Pt 1), 1-14 (2003).
2. Homma Y, Ozono S, Numata I, Seidenfeld J,et al. Alpha-Difluoromethylornithine inhibits cell growth stimulated by a tumor-promoting rat urinary fraction. Carcinogenesis. 1985 Jan;6(1):159-61.
3. Weeks CE, Herrmann AL, Nelson FR, Slaga TJ. Alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci U S A. 1982 Oct; 79(19):6028-32.
| Cas No. | 96020-91-6 | SDF | |
| 别名 | 依氟鸟氨酸盐酸盐一水合物,DFMO,Eflornithine | ||
| 化学名 | 2-(difluoromethyl)-ornithine, monohydrochloride, monohydrate | ||
| Canonical SMILES | FC(F)C(C(O)=O)(N)CCCN.Cl.O | ||
| 分子式 | C6H12F2N2O2 • HCl [H2O] | 分子量 | 236.6 |
| 溶解度 | ≥ 11.55mg/mL in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.2265 mL | 21.1327 mL | 42.2654 mL |
| 5 mM | 0.8453 mL | 4.2265 mL | 8.4531 mL |
| 10 mM | 0.4227 mL | 2.1133 mL | 4.2265 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。